Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro

Blood Cells Mol Dis. 2012 Mar 15;48(3):199-201. doi: 10.1016/j.bcmd.2012.01.005. Epub 2012 Feb 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Aurora Kinases
  • Benzamides
  • Benzimidazoles / pharmacology*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cells, Cultured
  • Humans
  • Imatinib Mesylate
  • Janus Kinases / antagonists & inhibitors*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology*
  • Piperazines / pharmacology*
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Pyrimidines / pharmacology*
  • Urea / analogs & derivatives*
  • Urea / pharmacology

Substances

  • 1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)urea
  • Antineoplastic Agents
  • Benzamides
  • Benzimidazoles
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Urea
  • Janus Kinases
  • Aurora Kinases
  • Protein Serine-Threonine Kinases